Bristol Myers Squibb bags European Commission nod for Subcutaneous formulation of Opdivo across multiple solid tumor indications Ruchika Sharma29 May 2025 10:00 AM ISTPrinceton: Bristol Myers Squibb has received approval from the European Commission (EC) for a new Opdivo (nivolumab) formulation...
Bristol Myers Squibb gets European Commission nod for Opdivo plus Yervoy for Hepatocellular Carcinoma Ruchika Sharma9 March 2025 12:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the...
Bristol Myers Squibb application for Opdivo Plus Yervoy for MSI-H/ dMMR colorectal cancer accepted by USFDA Ruchika Sharma27 Feb 2025 12:46 PM ISTBristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application...
Injectable version of Bristol Myers Squibb cancer drug Opdivo gets USFDA okay Ruchika Sharma28 Dec 2024 12:30 PM ISTOpdivo Qvantig offers a faster delivery for patients to receive this immunotherapy treatment option in three to five minutes compared to 30 minute IV...
Bristol Myers Squibb gets European Commission nod for Opdivo plus Yervoy to treat colorectal cancer Ruchika Sharma25 Dec 2024 4:52 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus...
Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic Colorectal Cancer Ruchika Sharma18 Nov 2024 4:57 PM ISTPrinceton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
USFDA accepts application for Opdivo plus Yervoy for unresectable hepatocellular carcinoma Ruchika Sharma22 Aug 2024 4:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License...
Bristol Myers Squibb gets EMA validation of application for Opdivo plus Yervoy for Hepatocellular Carcinoma Ruchika Sharma21 July 2024 3:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Medicines Agency (EMA) has validated its Type II variation application for...
Setback: Bristol Myers drug combo fails to meet main goal in kidney cancer trial Ruchika Sharma30 July 2022 1:15 PM ISTRenal cell carcinoma (RCC) is the most common type of kidney cancer in adults
Bristol Myers Opdivo fails to meet primary endpoint in CheckMate -901 trial Ruchika Sharma19 May 2022 10:15 AM ISTUrothelial carcinoma, which most frequently begins in the cells that line the inside of the bladder, accounts for approximately 90% of bladder cancer...
FDA Approves Drug Combo for treatment of malignant pleural mesothelioma Hina Zahid2 Oct 2020 6:30 PM ISTThe U.S. Food and Drug Administration approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with...
Bristol Myers gets USFDA nod to Opdivo, Yervoy combo for treating Lung Cancer Patients Farhat Nasim18 May 2020 5:18 PM ISTNew Delhi: Bristol Myers Squibb(BMS) recently announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for...
